Early results from preclinical and clinical studies have shown the potential benefits of GLP-1RAs in improving glycaemic control, weight management, endothelial function, atherosclerotic plaque stability, systemic inflammation, renal function, BP levels and AF risk
As a control group, pwIIH electing for UCWM only were matched for age-, sex- and BMI in a 1:2 ratio
EX microspheres are a long-acting release of EX
This Video I made addresses this angle
Implications for insurers Insurers should consider the impact of AOMs across their business: Assess how AOMs may impact protection, morbidity, and longevity experience Review trend assumptions to identify whether changes are needed Establish processes to keep on top of this fast-moving space Consider new lapse risks Assess how AOMs might affect underwriting and claims Insured impacts and reviewing trend assumptions Insurers should consider adjustments to their specific mortality and morbidity improvement assumptions to reflect AOMs
Addressing the link between obesity and PsA offers an opportunity to reduce PsA prevalence and improve its management by promoting weight loss, a modifiable risk factor[38]
